MOMM Diagnostics
MOMM Diagnostics develops diagnostic tests based on biosensor technology. The first product is a single blood-drop test for preeclampsia, a pregnancy disorder, which can have devastating effect on the health of the mother and the unborn baby.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
CHF1.2m | Grant | ||
| Total Funding | 000k | ||
| EUR | 2018 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Company filings or news article
Related Content
MOMM Diagnostics is a Swiss startup founded in 2018, emerging from a collaboration between Avails Medical, Inc. and the Swiss research institute Empa. The company is revolutionizing the field of prenatal care with its innovative rapid diagnostic test for preeclampsia, a dangerous pregnancy condition. Preeclampsia can lead to serious complications for both mothers and babies if not detected early. MOMM Diagnostics aims to provide healthcare professionals with accurate and timely diagnostic tools to improve maternal and neonatal health outcomes worldwide.
The company operates in the healthcare diagnostics market, specifically focusing on prenatal care. Its primary clients are healthcare professionals, including obstetricians, gynecologists, and prenatal care providers who need reliable and quick diagnostic tools to ensure the well-being of pregnant women and their babies.
MOMM Diagnostics' business model revolves around the development and commercialization of its rapid preeclampsia test, which utilizes the company's proprietary eFlow technology. This technology allows for the fastest and most precise detection of preeclampsia using a simple fingerstick blood sample, delivering results in minutes. By offering this cutting-edge diagnostic tool, MOMM Diagnostics aims to bridge the gap in prenatal care, providing accessible and reliable solutions to healthcare providers.
The company generates revenue by selling its diagnostic tests and related technologies to healthcare institutions and professionals. Additionally, MOMM Diagnostics seeks investment from stakeholders who share its vision of advancing the field of diagnostics and improving patient outcomes.
In summary, MOMM Diagnostics is dedicated to transforming maternal healthcare through its groundbreaking rapid preeclampsia test, empowering healthcare professionals with the tools they need for early and accurate diagnosis.
Keywords: prenatal care, preeclampsia, rapid diagnostic test, maternal health, healthcare professionals, eFlow technology, innovation, Swiss startup, healthcare diagnostics, patient outcomes.